Clinical Trial Update: A Study of Usage of Brigatinib in the Treatment of Adult Participants for Approved Indications In South Korea

View source ↗

Summary

Ongoing recruitment in South Korea for brigatinib to treat adults with approved indications in non-small cell lung cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Alunbrig (Brigatinib)

Snippet

Sponsor: Takeda | Conditions: Carcinoma, Non-Small-Cell Lung, Anaplastic Lymphoma Kinase | Status: RECRUITING